| |
Idenix/Novartis Apply for Telbivudine European OK
|
| |
| |
February 07, 2006 11:13 AM ET
CAMBRIDGE, Mass. (AP) - Idenix Pharmaceuticals Inc. and Novartis AG said Tuesday that they have applied for marketing approval of their hepatitis B treatment in Europe.
Idenix and Novartis said that they have submitted an application to the European Medicines Agency to sell a 600 milligram dose of telbivudine to treat chronic hepatitis B -- the most common serious liver infection, which can cause liver failure or scarring, liver cancer and even death.
The companies submitted an application to the Food and Drug Administration in January, and plans to submit applications for key Asian markets in the first quarter.
Idenix shares fell 79 cents, or 3.6 percent, to $20.98 in morning trading on the Nasdaq, and American depositary shares of Novartis declined 17 cents to $54.53 on the New York Stock Exchange.
|
|
| |
| |
|
|
|
